Perspective Therapeutics (CATX) announced certain business updates and strategic priorities for the next 12-18 months. Key updates include: Continued strong patient recruitment in neuroendocrine tumors for lead program VMT-alpha-NET sets the stage for submissions of robust clinical data package for presentation to more medical conferences in 2026, as well as regulatory engagement; VMT-alpha-NET continues to be well-tolerated and shows durable disease control and deepening of tumor response with longer follow-up as reported at ASCO-GI 2026; Clinical updates expected in mid to late 2026 for VMT01 targeting melanoma and PSV359 targeting FAP across multiple solid tumors, as well as potential additions to the clinical pipeline to be guided by first-in-human images
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CATX:
- Perspective Therapeutics Reports Positive Interim Neuroendocrine Tumor Data
- Perspective presents interim results from Phase 1/2 trial of 212PbVMT-a-NET
- Perspective Therapeutics Updates Corporate Presentation on Advancements
- Perspective Therapeutics assumed with a Buy at Truist
- Perspective Therapeutics price target lowered to $7 from $18 at UBS